A recent article published in BioMed Research International reported that diabetic nephropathy one of the most important microvascular complications of diabetes mellitus is responsible for 40 50 of all cases of end stage renal disease. It was emphasized that therapeutic strategies in diabetic nephropathy need to be targeted towards the pathophysiology of the disease. The earlier these therapeutic strategies can bring about positive effects on vascular changes and prevent the vasculature in patients with diabetes from deteriorating the better the renal function can be preserved. Studies evaluating anti inflammatory and anti oxidative strategies in diabetic nephropathy demonstrate the need and value of these novel treatment avenues. This article revealed that CaD an established vasoactive and angioprotective drug has shown a unique multi target mode of action in several experimental studies and in different animal models of diabetic microvascular complications. The article elaborated that CaD reduces oxidative stress and inhibits growth factors such as fibroblast growth factor and vascular endothelial growth factors. Recent findings have demonstrated a strong rationale for its use in reducing urine albumin excretion rate and markers of inflammation as well as for improving endothelial function. It was further stated that the beneficial effects of this drug make it an attractive therapeutic compound especially in the early stages of the disease. Prospective clinical trials were recommended in order to further confirm these findings.